Characteristics of patients who developed transient anti-adalimumab antibodies
{{output}}
Background: Adalimumab is a monoclonal antibody approved for the treatment of autoimmune diseases and non-infectious uveitis (NIU). It targets tumor necrosis factor alpha, a key mediator in inflammation. However, the development ... ...
